(Date:11/23/2009)...Call/--CornerstoneTherapeuticsInc.(Nasdaq: CRTX ),...developingandcommercializingsignificantproductspri...uncedthatCraigA.Collard,PresidentandChiefExecutive...tAnnualPiperJaffrayHealthCareConferenceat3:30PMETo...NewYorkCity. ,, AliveaudioandarchivedwebcastofC...
(Date:11/20/2009)...FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN ...nistration (FDA) provided written acknowledgement ...cation (BLA) for PROVENGE® (sipuleucel-T) is ...ription Drug User Fee Act (PDUFA) date of May 1, 2...mended BLA. Dendreon is seeking licensure for PRO...
(Date:11/20/2009)...recently announced that a free webinar, “Rol... Particle Characterization”, will be present...ication of in situ particle characterization is de...series of roller compaction runs while varying raw...es. , (PRWEB) November 20...
(Date:11/19/2009)...irstCall/ -- Omeros Corporation (Nasdaq: OMER ) t... third quarter ended September 30, 2009. For the t...ted a net loss of $3.9 million, or $1.34 per share....54 per share, for the same period in 2008. For th...y reported a net loss of $15.5 million, or $5.29 p...
Breaking Biology Technology:Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference 2Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3Roller Compaction Process Optimization Using At-Line Particle Characterization 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8... Steerable lead also receives reimbursement approv...ct immediately, NATICK, Mass., April 14 Boston S...d Japanese Ministry of Health, Labor,and Welfare (...tricular,lead for use with cardiac resynchronizati...e. The Company also received reimbursement approva...
...LL, N.C., April 14 For 88 percent of,companies, f...es leadership,development programs, which cover a ...n techniques for leading, influencing and coaching...leaders attend the programs,perhaps due to having ...ing, according to a member-driven research study c...
...HIA, April 14 eResearchTechnology,Inc. (eRT), (Na...oday their,alliance to provide integrated Cardiac ... researchers worldwide., eResearchTechnology is a...hic (ECG), eClinical technology, ePRO, and other s...cal device, and related,industries. nSpire Health ...
Other Biology Technology:Boston Scientific Announces Japanese Approval of Heart Failure Lead 2Boston Scientific Announces Japanese Approval of Heart Failure Lead 3Developing Sales Leaders: Benchmarks Reveal Tactics that Will Propel Your Business 2eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services 2eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services 3Mouse Anti-SOCS3 Monoclonal Antibody, Unconjugated, Clone SOC-25 from BioLegend
Mouse Anti-Synapsin I Monoclonal Antibody, Unconjugated, Clone 223 from IMGENEX
PBMC Cell Chip-IHC from 3H Biomedical AB
UCB Monocyte Cell Chip-IHC from 3H Biomedical AB
Biology Products: